Clinica Doctor Balcangiu-Stroescu

Why do we become dependent on certain foods?

Why do we become dependent on certain foods?
Useful information
February 28, 2026Andra-Elena Balcangiu-Stroescu

Neurobiology of appetite and the hidden mechanisms of reward

Food addiction is not a metaphor. It is a real neurobiological phenomenon.

Certain foods – especially ultra-processed ones, rich in sugar, fats, and salt – activate the dopaminergic reward system, the same brain network involved in nicotine or alcohol dependence.

At the moment of consumption, dopamine is released in the nucleus accumbens, generating an intense state of pleasure and anticipation. However, frequent repetition leads to neuronal adaptation: decreased sensitivity of dopamine receptors and the onset of tolerance.

The result?
Larger quantities are needed for the same satisfaction, the individual has diminished control and exhibits compulsive behavior.

Hyperpalatable foods

The food industry optimizes foods by adding:

  • sugar
  • fats
  • salt
  • artificial flavors

The goal is not merely pleasant taste, but maximizing the reward response.

Chocolate, crunchy snacks, pizza, industrial pastries, sweetened beverages, or fast food are not just caloric – they are neuro-activators.

These products do not induce true satiety, but rather stimulate continuous anticipation.

Sugar – emotional and metabolic stimulant

Sugar has a dual impact:

  1. Neurochemical – increases dopamine and temporarily reduces cortisol, providing emotional comfort.
  2. Metabolic – produces rapid spikes in blood glucose followed by abrupt drops, which reactivates appetite.

Over time, a cycle of seeking–consumption–guilt–repetition can become established.

Important: the predisposition toward sweets is evolutionary. In the past it meant secure energy. Today, unlimited availability completely changes the biological context.

Food withdrawal – physiological reality

Abrupt reduction in intense sugar consumption can generate transitory symptoms:

  • irritability
  • headache
  • fatigue
  • increased appetite
  • difficulty concentrating

Average duration: 3–7 days.

This confirms the neuroadaptive component of the process.

Recovery – recalibration of the reward system

"Breaking" a food addiction does not mean permanent absence of appetite.
It means restoring control.

The process involves:

  • eating structure (regular meals, protein, fiber)
  • progressive reduction of trigger foods
  • sleep optimization and stress management
  • psychological intervention when necessary

First changes appear in 3–4 weeks. Consolidation of new mechanisms requires 2–3 months of consistency.

Conclusion

Food dependence is the intersection of neurobiology and emotion. It is not a character flaw. It is a hyperactivated reward system in a hyper-stimulating food environment.

Understanding the mechanism allows for strategic intervention – not guilt, not radical restrictions, but progressive and intelligent recalibration. The brain adapts.
And it can adapt toward balance.

Also Read

Related Articles

A single injection for cholesterol — from dreams to first human results
Useful information

A single injection for cholesterol — from dreams to first human results

A Phase 1 trial published in the New England Journal of Medicine (November 2025) brings remarkable results: a single infusion of CTX310, a CRISPR-Cas9 therapy developed by Cleveland Clinic and CRISPR Therapeutics, reduced LDL cholesterol by up to 49% and triglycerides by up to 55% in patients with refractory dyslipidemia — without serious adverse events. The mechanism is unique: instead of blocking a protein or interfering with its mRNA, CTX310 permanently edits the ANGPTL3 gene in hepatic cells, mimicking a natural mutation associated with reduced cardiovascular risk throughout life. The therapy is currently in Phase 1b clinical stage, with updates expected in the second half of 2026. It is not approved and does not replace current treatments. Read the full article for clinical context, comparison with statins and PCSK9 inhibitors, and what these data mean for patients. Medical Disclaimer This article presents results from a Phase 1 clinical trial in an early-stage research phase. The therapy described is not approved and is not available as standard treatment. The information is for educational purposes only. Consult your physician for any medical decision.

June 1, 2026Andra-Elena Balcangiu-Stroescu

Ready to schedule?

Book an appointment online or call us directly.

+40 747 777 107